Patient no. | Breslow depth (mm) | Clark level (I–IV) | Lymphocytic infiltration* (0–3) | % of CD25+ TILs | % of CD25+ melanoma cells | CD3+ | CD4+ | CD8+ | CD16+ | IL2 scan | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
V | T/B | |||||||||||
1 | 0.8 | III | 2 | 15 | 0 | 61 | 38 | 22 | 16 | N | 0.99 | |
2 | 2.5 | III | 1 | — | — | 75 | 40 | 31 | 16 | P | 1.48 | |
3 | 2.75 | III | 1 | 30 | 0 | 35.5 | 14.3 | 20.8 | 2.1 | P | 1.25 | |
4 | 2.8 | IV | 1 | 60 | 20 | 27.9 | 17.8 | 12.2 | 40.1 | P | 1.81 | |
5 | 0.6 | II | 2 | 0 | 0 | 67.7 | 43.2 | 26.5 | 12 | N | 1.00 | |
6 | 2.5 | IV | 1 | — | — | 39.1 | 24.7 | 8.6 | 14.4 | P | 1.11 | |
7 | 0.6 | II | 1 | 5 | 0 | 67.7 | 40 | 6.4 | 6.6 | P | 1.17 | |
8 | 0.8 | I | 2 | 35 | 5 | 79.9 | 62 | 16.5 | 6.6 | N | 0.95 | |
9 | 0.3 | II | 2 | 10 | 0 | 58.8 | 41.3 | 15.1 | 14.1 | P | 1.14 | |
10 | 0.8 | II | 1 | — | — | 75.7 | 37.8 | 31.5 | 16.3 | P | 1.20 | |
11 | 1 | III | 2 | 10 | 0 | 58.4 | 37.2 | 17 | 5.6 | P | 1.14 | |
12 | 1 | III | 1 | 20 | 0 | 51.3 | 28 | 16.5 | 7.3 | P | 1.19 | |
13 | 1.5 | III | 1 | 25 | 0 | 62 | 38.2 | 28 | 12 | P | 1.28 | |
14 | 1.5 | III | 1 | 60 | 100 | 70 | 35 | 22 | 13 | P | 1.44 | |
15 | 1.25 | III | 1 | 0 | 0 | 78.8 | 55.7 | 23.4 | 13 | N | 1.00 | |
16 | 0.3 | II | 1 | 10 | 90 | 79 | 54.9 | 24.4 | 6.9 | N | 1.00 | |
17 | 1.3 | III | 1 | — | — | 72.6 | 36.6 | 34.5 | 8.9 | P | 1.12 | |
18 | 7.5 | IV | 1 | 18 | 100 | 79 | 59.8 | 19.4 | 19.3 | P | 1.13 | |
19 | 1 | III | 1 | 5 | 80 | 75.8 | 48.7 | 25.8 | 8.6 | N | 0.95 | |
20 | 7 | IV | 1 | 22 | 80 | — | — | — | — | P | 1.13 | |
21 | 0.9 | II | 3 | 5 | 0 | 78.4 | 50.5 | 25.7 | 11.5 | P | 1.25 |
V = visual analysis; N = negative; P = positive.
↵* Extent of perilesional lymphocytic infiltration (TILs).